BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor Models

Jeremy M. Kinder, Aaron E. Foster, Chanel Athena-Estrada et al.|Blood|2022

Cited by 1